Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002924 · ClinicalTrials.gov registry record
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
A clinical trial, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- 184
- Enrollment target
NCT00002924: Completed study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00002924 is a clinical trial that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 184 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002924 has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- 184 participants
- Enrollment target
Study Summary
RATIONALE: Gene mutations may make prostate cancer cells unable to attach to androgens. This may permit the growth of prostate cancer. Gene testing may improve the identification of patients with advanced prostate cancer. PURPOSE: Clinical trial to study the androgen receptor gene in patients with prostate cancer that is not responsive to hormone therapy.
Interventions
- OTHER mutation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 1997-01 |
| Est. Completion | 2006-06 |
What the finished NCT00002924 record still lists
NCT00002924 is an observational study that tracks outcomes without assigning an intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which mutation analysis is the first listed.
NCT00002924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002924 about?
NCT00002924 is a clinical study titled "Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy". RATIONALE: Gene mutations may make prostate cancer cells unable to attach to androgens. This may permit the growth of prostate cancer. Gene testing may improve the identification of patients with advanced prostate cancer. PURPOSE: Clinical trial to study the androgen receptor gene in patients with ...
What is the current status of trial NCT00002924?
This trial is currently completed. The enrollment target is 184 participants. The study started on 1997-01. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00002924?
The interventions under investigation include: mutation analysis (OTHER).
Who is sponsoring clinical trial NCT00002924?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia